🧾 What This Document Is

This is a "current report" (Form 6-K) filed with the SEC. It's not a routine earnings report. Think of it as an important, timely announcement from Regencell. The core news is that the company has set up a financing tool to sell up to $500 million of its stock over time, directly into the market. This is called an "at-the-market" or ATM offering.

🏢 What The Company Does

👉 In simple terms, Regencell is an early-stage biotech company. It's researching and developing treatments based on Traditional Chinese Medicine (TCM) for brain-related disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Their goal is to become a global leader in natural, holistic treatments for these conditions. This context is crucial—they are pre-revenue and need capital to fund their research and operations.

💰 The Financing Announcement: Key Numbers

The headline figure is the size of the potential offering:

• Amount: Up to $500,000,000 (Five Hundred Million Dollars) of ordinary shares.
• Share Price: Not fixed. Shares will be sold at "market prices" prevailing at the time of each sale. This means the price will fluctuate.
• Obligation: The company is not obligated to sell any shares. This is a ceiling, not a requirement. They can choose when and how much to sell.

🚀 How the ATM Offering Works

This isn't a single, big sale. It's a flexible pipeline for selling shares.

• Sales Agent: Regencell hired Univest Securities, LLC to act as its agent.
• Method: Shares can be sold directly on the Nasdaq Capital Market (where RGC trades), through market makers, or in private deals, all at current market prices.
• Timing & Control: The company decides when to instruct the agent to sell. The speed and amount are entirely up to Regencell's needs and market conditions. This gives them significant control over the process.

🔮 Why Announce This Now & What It Signals

👉 For an early-stage biotech, cash is the lifeblood for funding clinical trials, R&D, and daily operations without taking on debt. This filing signals that Regencell is proactively securing a large, flexible source of capital. By filing a "shelf registration" (Form F-3) that became effective immediately, they've created a financial runway to draw from as needed to execute their business plan over the coming months or years.

⚖️ The Big Picture: Strengths & Risks

• 👍 Strength (Financial Flexibility): This tool provides potential access to substantial capital without the pressure of a one-time, priced offering. It allows the company to raise money opportunistically when it needs it or when the stock price is favorable.
• ⚠️ Risk (Dilution & Market Pressure): Every new share sold through this program increases the total number of shares outstanding. This dilutes the ownership percentage of existing shareholders. Furthermore, announcing a large ATM can sometimes put downward pressure on a stock price, as investors anticipate future sales.

📅 Key Dates & Procedural Details

• Announcement Date: March 30, 2026.
• Registration Filed: The shelf registration (Form F-3) was also filed on March 30, 2026, and became effective immediately.
• Prospectus Access: Investors can get the full legal documents from the SEC's website or by contacting the sales agent, Univest Securities, LLC, at [email protected] or by calling +1 (212) 343-8888.

🧠 The Analogy

Setting up an ATM offering is like a startup founder getting a high-limit credit card. They don't have to max it out all at once (that would be risky and dilutive). Instead, they can use it strategically to pay for essential expenses (like lab research and clinical trials) as they come due, with the understanding that using the card means they're giving away a small piece of the company each time.

📇 Key Contacts & People

• Company Contact: James Chung, Investor Relations
• Email: [email protected]
• Sales Agent Contact: Univest Securities, LLC
• Agent Email: [email protected]
• Agent Phone: +1 (212) 343-8888

🧩 Final Takeaway

Regencell Bioscience has established a $500 million financial safety valve to fund its development of Traditional Chinese Medicine treatments for ADHD and Autism. While this provides crucial capital for an early-stage company, investors should remember that drawing from this fund will dilute their ownership over time. It's a strategic move to fuel growth, but with a clear cost.